Skip to main content

A Toronto Stock Exchange logo is seen in Toronto in this file photo.

Mark Blinch/Reuters

Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report's recommendations. For more on The Globe's disclaimers please read here. The following is excerpted from the report:

The TSX Composite Earnings Scorecard is the most comprehensive and up-to-the-minute compilation of aggregated earnings growth and market intelligence covering the companies included in the TSX Composite Index. This report combines Thomson Reuters' unrivaled historical earnings database, in-depth coverage of sell-side analysts' bottom-up corporate earnings estimates, and the analytic capabilities of Thomson Reuters Proprietary Research Group and desktop solutions.

EARNINGS HIGHLIGHTS

Story continues below advertisement

Q2 2017 Y/Y Blended Earnings Growth Estimates

  • TSX Composite (.GSPTSE) = 20.8 per cent
  • Ex-Energy = 13.7 per cent
  • Valeant Pharmaceuticals International Inc. = -29.0 per cent
  • Healthcare Ex- VRX = -1.2 per cent
  • TSX Composite Ex-VRX = 21.8 per cent

Q2 2017 Performance vs. Earnings Expectations

Ninety-eight per cent of the TSX Composite companies have reported Q3 2017 EPS. Of the 239 companies in the index that have reported earnings to date for Q2 2017:

  • 54.0 per cent reported above analyst expectations
  • 34.7 per cent reported below analyst expectations

Q3 2017 Y/Y Blended Earnings Growth Estimates

  • TSX Composite = 14.7 per cent
  • Ex-Energy = 7.7 per cent
  • Valeant Pharmaceuticals = -35.5 per cent
  • Healthcare Ex- VRX = -39.0 per cent
  • TSX Composite Ex-VRX = 15.7 per cent

REVENUE HIGHLIGHTS

Q2 2017 Y/Y Blended Revenue Growth Estimates

  • TSX Composite = 7.3 per cent
  • Ex-Energy = 3.4 per cent
  • Valeant Pharma. (VRX.TO) = -10.9 per cent
  • Healthcare Ex-Valeant Pharma. = 7.9 per cent
  • TSX Composite Ex-Valeant Pharma. = 7.5 per cent

Q2 2017 Performance vs. Revenue Expectations

Story continues below advertisement

Of the TSX Composite companies that have reported revenue to date for Q3 2017:

  • 60.2 per cent reported above analyst expectations
  • 39.4 per cent reported below analyst expectations

Q3 2017 Y/Y Blended Revenue Growth Estimates

  • TSX Composite (.GSPTSE) = 8.1 per cent
  • Ex-Energy = 6.6 per cent
  • Valeant Pharmaceuticals = -14.0 per cent
  • Healthcare Ex-Valeant Pharma = 5.9 per cent
  • TSX Composite Ex-Valeant Pharma = 8.4 per cent

Click here to see a full copy of the Thomson Reuters I/B/E/S TSX Composite Earnings Scorecard.

Globe app users click here for the full report

Read other research reports here.

Should you be investing in ETFs or mutual funds? Rob Carrick, personal finance columnist, lays out specific investments, services and brands that are currently great deals for Canadian investors.
Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

If your comment doesn't appear immediately it has been sent to a member of our moderation team for review

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.